Celldex Therapeutics earnings were -$300.5M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CLDX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$73.5M, down 6.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CLDX reported annual earnings of -$258.8M, with 63.9% growth.
Celldex Therapeutics Earnings Reports & History FAQ
What were Celldex Therapeutics's earnings last quarter?
On CLDX's earnings call on Aug 6, 2026, Celldex Therapeutics (NASDAQ: CLDX) reported Q2 2026 earnings per share (EPS) of -$0.94, up 10.59% year over year. Total CLDX earnings for the quarter were -$73.50 million. In the same quarter last year, Celldex Therapeutics's earnings per share (EPS) was -$0.85.
Is Celldex Therapeutics profitable or losing money?
As of the last Celldex Therapeutics earnings report, Celldex Therapeutics is currently losing money. Celldex Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$300.55 million, a 50.57% increase year over year.
What was CLDX's earnings growth in the past year?
As of Celldex Therapeutics's earnings date in Aug 6, 2026, Celldex Therapeutics's earnings has grown year over year. CLDX earnings in the past year totalled -$300.55 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.